Free Trial

Enlivex Therapeutics (ENLV) Institutional Ownership

Enlivex Therapeutics logo
$0.72 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$0.73 +0.01 (+1.46%)
As of 05/22/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Institutional Ownership Changes (13F Filings) for Enlivex Therapeutics (NASDAQ:ENLV)

Current
Institutional Ownership
Percentage
1.02%
Number of
Institutional Buyers
(last 12 months)
9
Total
Institutional Inflows
(last 12 months)
$671.43K
Number of
Institutional Sellers
(last 12 months)
4
Total
Institutional Outflows
(last 12 months)
$617.98K
Get ENLV Insider Trade Alerts

Want to know when executives and insiders are buying or selling Enlivex Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Chart & View Institutional Buying and Selling Data

ENLV Institutional Buying and Selling by Quarter

Enlivex Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/19/2026 Bank of America Corp DE130,401$121K0.0%+53.2%0.055%
5/14/2026 Renaissance Technologies LLC128,192$119K0.0%-59.1%0.054%
2/23/2026 Virtu Financial LLC47,381$33K0.0%N/A0.020%
2/19/2026 Invesco Ltd.60,920$43K0.0%N/A0.026%
2/18/2026 XTX Topco Ltd61,800$43K0.0%+44.8%0.026%
2/12/2026 Jane Street Group LLC74,082$52K0.0%+244.1%0.031%
2/12/2026 HRT Financial LP153,990$108K0.0%+719.4%0.065%
2/12/2026 Renaissance Technologies LLC313,628$221K0.0%+99.4%0.132%
11/17/2025 Susquehanna International Group LLP54,850$57K0.0%N/A0.226%
11/17/2025 Citadel Advisors LLC68,936$72K0.0%-12.8%0.284%
10/24/2025 Citizens Financial Group Inc. RI231,424$241K0.0%N/A0.953%
8/14/2025 Jane Street Group LLC61,052$68K0.0%-24.4%0.258%
8/14/2025 Armistice Capital LLC1,413,306$1.58M0.0%-20.7%5.976%
5/19/2025Jane Street Group LLC80,759$78K0.0%+527.4%0.341%
5/15/2025Armistice Capital LLC1,781,931$1.73M0.0%-19.3%7.534%
2/17/2025Millennium Management LLC633,847$742K0.0%N/A2.961%
2/14/2025Two Sigma Securities LLC22,362$26K0.0%N/A0.104%
2/13/2025Renaissance Technologies LLC158,992$186K0.0%+112.6%0.743%
10/23/2024Sigma Investment Counselors Inc.30,000$50K0.0%N/A0.140%
8/15/2024Armistice Capital LLC1,700,571$2.42M0.0%N/A8.148%
8/12/2024XTX Topco Ltd24,820$35K0.0%N/A0.119%
5/1/2023Compagnie Lombard Odier SCmA65,000$225K0.0%+30.0%0.350%
2/9/2023Group One Trading L.P.13,499$53K0.0%+2,689.0%0.073%
7/11/2022ARK Investment Management LLC331,001$1.66M0.0%-23.8%1.802%
4/27/2022Compagnie Lombard Odier SCmA50,000$279K0.0%+16.3%0.273%
4/20/2022Belvedere Trading LLC14,473$101K0.0%-13.9%0.079%
4/19/2022ARK Investment Management LLC434,343$2.43M0.0%+24.3%2.372%


ENLV Institutional Ownership - Frequently Asked Questions

During the previous two years, 14 institutional investors and hedge funds held shares of Enlivex Therapeutics. The most heavily invested institutionals were Armistice Capital LLC ($1.58M), Millennium Management LLC ($742K), Citizens Financial Group Inc. RI ($241K), Bank of America Corp DE ($121K), Renaissance Technologies LLC ($119K), HRT Financial LP ($108K), and Citadel Advisors LLC ($72K).Learn more on Enlivex Therapeutics' institutional investors.

1.02% of Enlivex Therapeutics' stock is owned by institutional investors. Learn more on ENLV's institutional investor holdings.

Of the 13 institutional investors that purchased Enlivex Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Armistice Capital LLC ($1.70M), Millennium Management LLC ($633.85K), Renaissance Technologies LLC ($240.54K), Citizens Financial Group Inc. RI ($231.42K), HRT Financial LP ($135.20K), Jane Street Group LLC ($120.44K), and Invesco Ltd. ($60.92K).

Institutional investors have bought a total of 803,097 shares in the last 24 months. This purchase volume represents approximately $671.43K in transactions.

The following institutional investors have sold Enlivex Therapeutics stock in the last 24 months: Armistice Capital LLC ($368.63K), Renaissance Technologies LLC ($185.44K), Jane Street Group LLC ($19.71K), and Citadel Advisors LLC ($10.16K).

Institutional investors have sold a total of 583,932 shares in the last 24 months. This volume of shares sold represents approximately $617.98K in transactions.



This page (NASDAQ:ENLV) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners